Diabetes Research Program
As the incidences of type 1 and type 2 diabetes rise in the United States and throughout the world, the risk of devastating complications soars as well. Diabetes is a leading cause of heart attack, stroke, blindness, kidney failure, and amputations. These conditions and their complications severely burden the healthcare system.
Founded in July 2010 by Ann Marie Schmidt, MD, and Ravichandran Ramasamy, PhD, the Diabetes Research Program at NYU Langone is a laboratory group that studies the biochemical and molecular mechanisms of the complications of diabetes, particularly the links between hyperglycemia, inflammation, and diabetic tissue damage.
Our research focuses on key molecules linked to diabetes, such as aldose reductase, protein kinase C-β receptor for advanced glycation end products, or RAGE, and its cytoplasmic domain binding partner, diaphanous 1, or mDia1. We use innovative techniques to devise experiments, from animal models of diabetes to gene regulation studies in cultured cells. Our goal is to transform basic science discoveries into effective therapies for diabetes and its complications.
We are also dedicated to helping medical students, residents, and others who are interested in diabetes research gain experience in the basic research components of diabetes and its complications.
To contact the Diabetes Research Program, call 212-263-9471.